VEGFA and cancer: A combinatorial therapy targeting tumor hypoxia by using HIF-1α or VEGF-A inhibitors along with RT and immunotherapy (PD-L1 or other immune checkpoint inhibitor) may be beneficial for enhancing antitumor immunity in cancer patients.